Literature DB >> 17919627

Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors.

Ilhan Inci1, Wei Zhai, Stephan Arni, Demet Inci, Sven Hillinger, Didier Lardinois, Peter Vogt, Walter Weder.   

Abstract

BACKGROUND: The use of non-heart-beating donors (NHBDs) is an alternative strategy to increase the limited number of donors. The ex vivo evaluation has been proposed to assess the function of the lungs from NHBDs as an interim evaluation of the graft before transplantation. We evaluated the effect of a fibrinolytic agent, urokinase, in a pig ex vivo evaluation model.
METHODS: Domestic pigs (30-38 kg) were divided in 3 groups of 5 pigs each. In the Control Heart-Beating Donor (HBD) Group, the lungs were flushed, explanted, and stored in cold solution (4 degrees C) of low potassium dextran for 4 hours. The pigs in the other 2 study groups were non-heart-beating donors (NHBD), and their lungs were topically cooled for 1 hour in the closed chest after 3 hours of warm ischemia. Urokinase (100,000 IU) was added into the perfusate during reperfusion 1n 1 of the NHBD groups (NHBD-UROK). Hemodynamic and aerodynamic parameters were measured. The wet-to-dry weight ratio was calculated.
RESULTS: There was a significant difference between NHBD-UROK and NHBD Groups in pulmonary vascular resistance (22.5 +/- 3.06 vs 39.02 +/- 6.6 Wood Units, p = 0.032), partial pressure of arterial oxygen/fraction of inspired oxygen (250.8 +/- 23.3 vs 148.9 +/- 14.6 mm Hg, p = 0.032), oxygenation index (6.9 +/- 0.7 vs 15.9 +/- 3.2, p = 0.016), and wet-to-dry weight ratio (5.99 +/- 0.2 vs 7.74 +/- 0.3, p = 0.016). Pulmonary vascular resistance did not differ between the HBD and NHBD-UROK Groups but was significantly higher in the NHBD Group than in the HBD Group (p = 0.032).
CONCLUSION: Adding urokinase into the perfusate during ex vivo evaluation resulted in improved graft function by reducing pulmonary vascular resistance and increasing oxygenation after 3 hours of warm ischemia. This ex vivo evaluation model is feasible and may be used to recondition grafts from NHBDs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919627     DOI: 10.1016/j.healun.2007.07.033

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  11 in total

Review 1.  Lung transplantation, ex-vivo reconditioning and regeneration: state of the art and perspectives.

Authors:  Lorenzo Rosso; Alberto Zanella; Ilaria Righi; Mario Barilani; Lorenza Lazzari; Eleonora Scotti; Francesca Gori; Paolo Mendogni
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Adenosine A₂A agonist improves lung function during ex vivo lung perfusion.

Authors:  Abbas Emaminia; Damien J Lapar; Yunge Zhao; John F Steidle; David A Harris; Victor E Laubach; Joel Linden; Irving L Kron; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2011-10-31       Impact factor: 4.330

Review 3.  Machine perfusion of thoracic organs.

Authors:  Dirk Van Raemdonck; Filip Rega; Steffen Rex; Arne Neyrinck
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 4.  Donors after cardiocirculatory death and lung transplantation.

Authors:  Ilhan Inci
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

5.  The role of ex vivo lung perfusion in lung transplantation.

Authors:  Kate Colette Tatham; Kieran Patrick O'Dea; Kenji Wakabayashi; Nandor Marczin; Masao Takata
Journal:  J Intensive Care Soc       Date:  2014-12-09

6.  The impact of alteplase on pulmonary graft function in donation after circulatory death - An experimental study.

Authors:  Annika Liersch-Nordqvist; Mohammed Fakhro; Leif Pierre; Joanna Hlebowicz; Malin Malmsjo; Richard Ingemansson; Sandra Lindstedt
Journal:  Ann Med Surg (Lond)       Date:  2017-08-12

Review 7.  Application of Mesenchymal Stem Cells During Machine Perfusion: An Emerging Novel Strategy for Organ Preservation.

Authors:  Jiale Li; Qinbao Peng; Ronghua Yang; Kunsheng Li; Peng Zhu; Yufeng Zhu; Pengyu Zhou; Gábor Szabó; Shaoyi Zheng
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

8.  A standardized model of brain death, donor treatment, and lung transplantation for studies on organ preservation and reconditioning.

Authors:  Franco Valenza; Silvia Coppola; Sara Froio; Giulia Maria Ruggeri; Jacopo Fumagalli; Alessandro Maria Villa; Lorenzo Rosso; Paolo Mendogni; Grazia Conte; Caterina Lonati; Andrea Carlin; Patrizia Leonardi; Stefano Gatti; Nino Stocchetti; Luciano Gattinoni
Journal:  Intensive Care Med Exp       Date:  2014-06-10

9.  Lungs exposed to 1 hour warm ischemia without heparin before harvesting might be suitable candidates for transplantation.

Authors:  Annika Liersch-Nordqvist; Richard Ingemansson; Leif Pierre; Joanna Hlebowicz; Sandra Lindstedt
Journal:  J Cardiothorac Surg       Date:  2015-10-23       Impact factor: 1.637

10.  Functional, Metabolic and Morphologic Results of Ex Vivo Donor Lung Perfusion with a Perfluorocarbon-Based Oxygen Carrier Nanoemulsion in a Large Animal Transplantation Model.

Authors:  Ilhan Inci; Stephan Arni; Ilker Iskender; Necati Citak; Josep Monné Rodriguez; Miriam Weisskopf; Isabelle Opitz; Walter Weder; Thomas Frauenfelder; Marie Pierre Krafft; Donat R Spahn
Journal:  Cells       Date:  2020-11-18       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.